Identification of immune reconstitution and hematopoiesis restoration by scRNA-seq in bone marrow of multiple myeloma patients treated with high-dose melphalan following auto-HSCT

Multiple myeloma (MM) is a clonal plasma cell malignancy that arises within the bone marrow (BM), leading to disruptions in normal hematopoiesis, immune dysfunction, osteolytic bone lesions, anemia, and renal impairment[1][1]. Despite the significant advances in treatment, such as proteasome